Materialise NV (MTLS) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several negative factors: reduced revenue guidance, geopolitical and macroeconomic challenges, unfavorable foreign exchange impacts, and declining revenues in key segments. Despite some positive elements, like growth in the Medical segment and cost control efforts, the overall sentiment is negative due to reduced guidance and ongoing uncertainties, particularly in manufacturing and defense. The Q&A session did not alleviate concerns, with management providing vague responses about future growth and profitability. The lack of clear guidance and the negative financial trends suggest a likely negative stock price reaction.
Key Financial Performance
Consolidated Revenue EUR 66.3 million, a 3.5% decrease year-over-year. Reasons include macroeconomic headwinds and unfavorable foreign exchange effects, mainly due to a weaker U.S. dollar.
Gross Profit Margin 56.8%, slightly below the 57.2% achieved in Q3 2024. Reasons include stable gross profit but lower revenue.
Adjusted EBIT EUR 2.9 million, down from EUR 4.4 million in Q3 2024, representing a 4.4% margin. Reasons include lower revenue and cost control measures.
Net Profit EUR 1.8 million, compared to a net financial loss of EUR 1.1 million in Q3 2024. Reasons include improved financial results and limited foreign exchange losses.
Materialise Medical Revenue EUR 33.3 million, a 10% increase year-over-year. Reasons include growth in both medical software and medical device sales.
Materialise Software Revenue EUR 10.3 million, a 7% decrease year-over-year. Reasons include unfavorable foreign exchange impacts and macroeconomic/geopolitical uncertainty.
Materialise Manufacturing Revenue EUR 22.7 million, a 17% decrease year-over-year. Reasons include macroeconomic headwinds and weak performance in the automotive sector.
Adjusted EBITDA (Consolidated) EUR 8.4 million, down from EUR 9.9 million in Q3 2024, representing a 12.7% margin. Reasons include lower revenue but stable quarter-over-quarter performance due to cost control.
Materialise Medical Adjusted EBITDA EUR 10.2 million, with a margin of over 30%. Reasons include strong revenue growth and increased R&D investments.
Materialise Software Adjusted EBITDA EUR 1.8 million, with a margin of 18%. Reasons include effective cost management despite lower revenue.
Materialise Manufacturing Adjusted EBITDA Negative EUR 0.8 million, stable quarter-over-quarter. Reasons include lower revenue due to macroeconomic headwinds.
Operating Cash Flow EUR 10.4 million, up from EUR 6.9 million in Q3 2024. Reasons include strong free cash flow generation.
Capital Expenditures (CapEx) EUR 5.3 million, including EUR 3.1 million of non-recurring CapEx. Reasons include investments in machinery for the new ACTech plant and a solar panel park.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Cardiac Segment Expansion: Progress in the cardiac segment with the acquisition of FEops, specializing in AI-driven simulation technology for structural heart interventions. Released the next version of FEops' heart guide for transcatheter aortic valve replacement, adding predictive simulation features for reintervention planning. Clinical evidence demonstrated time savings of up to 91% for transcatheter aortic valve replacement procedures.
Mimics Enlight CMF Planner: Released a new version with AI algorithms for faster and more efficient planning, targeting trauma cases. Enables surgeons to plan procedures efficiently, saving costs and time during surgeries.
CO-AM Ecosystem: Launched low-code enabling technology to make SDKs more accessible, facilitating workflow automation and driving efficiencies in additive manufacturing operations.
Defense Sector Engagement: Increased focus on the defense sector, showcasing additive manufacturing capabilities at major trade exhibitions. Additive manufacturing addresses challenges in the defense industry, such as rapid and sustainable production of mission-critical components.
ACTech Expansion: Investments in machines for giga castings and large, complex parts for sectors like aquaculture, mining, maritime, and energy. Opened a second ACTech plant in 2024, enabling automation for small series production.
Revenue Growth in Medical Segment: Materialise Medical achieved an all-time revenue record of EUR 33.3 million in Q3 2025, growing by over 10% compared to Q3 2024. Growth driven by both medical software and medical device sales.
Cost Management: Disciplined cost control and targeted cost reduction measures stabilized adjusted EBIT and EBITDA compared to Q2 2025.
Transition to Cloud Subscription Model: Continued transition in the Software segment to a cloud subscription-based business model, with 83% of software revenue being recurring in Q3 2025, up from 74% in Q3 2024.
Focus on R&D Investments: Increased R&D investments, particularly in the Medical segment, to drive future growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Pressure: Overall revenue remained under pressure, with a 3.5% decline compared to the same quarter last year, driven by macroeconomic headwinds and unfavorable foreign exchange effects.
Manufacturing Segment Weakness: The Manufacturing segment experienced a 17% revenue decline year-over-year, attributed to macroeconomic challenges and weak demand in key sectors like automotive.
Software Segment Decline: The Software segment saw a 7% revenue decline, impacted by unfavorable foreign exchange rates and geopolitical uncertainty, particularly in the U.S. market.
Macroeconomic Headwinds: Macroeconomic volatility and geopolitical uncertainty continue to impact sales volumes and operational results across multiple segments.
Foreign Exchange Impact: Unfavorable foreign exchange effects, particularly due to a weaker U.S. dollar, negatively impacted revenue.
Cost Pressures: While cost control measures have been implemented, the company faces ongoing pressure to manage operational costs amidst declining revenues in key segments.
Deferred Revenue Decline: Deferred revenue related to software maintenance and license fees decreased in the third quarter, reflecting seasonal patterns but also indicating potential challenges in sustaining recurring revenue.
Defense Sector Challenges: While the company is making progress in the defense sector, the geopolitical landscape and breakdown of traditional alliances present uncertainties in this market.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for FY 2025: Materialise maintains its revenue guidance for fiscal year 2025 in the range of EUR 265 million to EUR 280 million.
Adjusted EBIT Guidance for FY 2025: The company expects adjusted EBIT to be in the range of EUR 6 million to EUR 10 million for fiscal year 2025.
Market Conditions Impact: Macroeconomic and geopolitical uncertainties continue to impact the business environment, particularly in the Manufacturing and Software segments.
Medical Segment Growth: Materialise Medical segment continues to grow, with plans to further increase R&D investments to drive future growth.
Software Segment Transition: The company is transitioning to a cloud subscription-based business model, with 83% of software revenue now recurring.
Manufacturing Segment Strategy: Materialise is investing in the huge and heavy segment, including machines for giga castings and large complex parts, to address challenges in sectors like automotive, aquaculture, mining, maritime, and energy.
Defense Sector Engagement: Materialise is expanding its presence in the defense sector, leveraging additive manufacturing to address industry challenges and strengthen strategic autonomy.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide an update on the relative exposure in the Medical segment, particularly focusing on CMF, HIPS, and the potential of cardiac and other areas for next year?
A:The majority of revenue comes from existing markets like CMF, orthopedics, and research and engineering, which are more mature. New markets, such as cardiac and respiratory, are smaller but expected to grow faster in the future. All three existing markets remain important.
Q:What is the size of aerospace and defense as a percentage of revenue, and what are the hopes for recovery in manufacturing?
A:Aerospace has shown continuous growth and remains a focus segment. Defense is a newer industry and not yet significant, but there is potential to leverage aerospace capabilities in defense. Manufacturing recovery depends on European industrial market recovery and automotive sector performance.
Q:Is the defense segment more focused on metals or polymers?
A:It is a combination of both. For example, in aerospace, polymers are used for interiors and tooling, with Airbus being a key client for polymer applications.
Q:What are the thoughts on manufacturing profitability and measures to improve it?
A:Cost reduction measures have been implemented and are showing impact, though not highly visible due to weak revenue. Recovery in European markets and the automotive sector is crucial for improving revenue and profitability.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numerical data on the size of aerospace and defense as a percentage of revenue and did not give detailed timelines or quantifiable impacts for recovery in manufacturing profitability.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
CO ecosystem
Enlight CMF
Europe
FEops
Medical Software
Mimics Enlight
SDKs
Software Manufacturing
Software segment
algorithm
automation
autonomy
build processor
case
casting
defense industry
device
drawing
evidence
example
feature planner
fragment
generation build
headwind
heart
introduction
line margin
machine
part
patient
procedure
saving
sector
security
simulation
software
surgeon
trauma
valve replacement
version
MTLS Transcript
Materialise NV (MTLS) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call presents a mixed outlook. While there is positive growth in the Medical segment and improved profitability, challenges such as foreign exchange headwinds, macroeconomic uncertainties, and a decline in Manufacturing revenue persist. The transition to a cloud-based model in Software is promising but poses short-term risks. The Q&A highlights sector-specific growth and challenges, but management's avoidance of certain specifics adds uncertainty. With stable revenue and improved margins but persistent headwinds, the overall sentiment is neutral, suggesting minimal short-term stock movement.
Materialise NV (MTLS) Q4 2025 Earnings Call Transcript
Unknown2-19
Despite positive factors like a share buyback program and strong revenue growth in the Medical segment, challenges persist. The Manufacturing segment struggles with profitability and macroeconomic headwinds. The Software segment faces revenue declines due to its transition. Additionally, the company's dependence on key verticals and economic uncertainties pose risks. While financial metrics show improvement, the cautious outlook on manufacturing and strategic dependencies balance out the positives, leading to a neutral sentiment.
Materialise NV (MTLS) Q3 2025 Earnings Call Transcript
Unknown10-28
The earnings call reveals several negative factors: reduced revenue guidance, geopolitical and macroeconomic challenges, unfavorable foreign exchange impacts, and declining revenues in key segments. Despite some positive elements, like growth in the Medical segment and cost control efforts, the overall sentiment is negative due to reduced guidance and ongoing uncertainties, particularly in manufacturing and defense. The Q&A session did not alleviate concerns, with management providing vague responses about future growth and profitability. The lack of clear guidance and the negative financial trends suggest a likely negative stock price reaction.
Materialise NV (MTLS) Q2 2025 Earnings Call Transcript
Unknown7-24
The earnings call presents a mixed picture: strong growth in the Medical segment and improved gross margins are positive, but significant declines in Software and Manufacturing revenues, coupled with a net financial loss, are concerning. The Q&A reveals cautious optimism about future growth, but also highlights uncertainties, especially in the Manufacturing segment. The slight downward revision in guidance and management's vague responses further temper positive sentiment, resulting in a neutral outlook for the stock price.
MTLS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
